Quince Therapeutics, Inc.
QNCX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662774
No open-market purchases or sales by Quince Therapeutics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $4.74M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Quince Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 131
- +27 vs. Q2 2021
- Shares held
- 19.2M
- +654.7K (+3.5%) vs. Q2 2021
- Total value
- $1.76B
- +$776.8M (+79.0%) vs. Q2 2021
- New holders
- 34
- 48 more added
- Sold out
- 7
- 28 more reduced
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting QNCX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $4.74M |
| Q1 2026 | 46 | $1.44M |
| Q4 2025 | 67 | $67.5M |
| Q3 2025 | 45 | $19.2M |
| Q2 2025 | 41 | $12.5M |
| Q1 2025 | 36 | $6.96M |
| Q4 2024 | 35 | $9.55M |
| Q3 2024 | 33 | $4.04M |
| Q2 2024 | 43 | $4.68M |
| Q1 2024 | 46 | $7.71M |
| Q4 2023 | 44 | $7.83M |
| Q3 2023 | 42 | $8.40M |
| Q2 2023 | 40 | $13.5M |
| Q1 2023 | 45 | $12.0M |
| Q4 2022 | 50 | $3.44M |
| Q3 2022 | 61 | $12.4M |
| Q2 2022 | 70 | $26.0M |
| Q1 2022 | 88 | $99.5M |
| Q4 2021 | 102 | $242.8M |
| Q3 2021 | 131 | $1.76B |
| Q2 2021 | 105 | $982.9M |
| Q1 2021 | 91 | $673.5M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Quince Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Sigma Advisers, LP | 38,500 | $3.53M | 0.01% | +29,100+309.6% | Added |
| Goldman Sachs Group Inc | 40,841 | $3.74M | 0.00% | +16,285+66.3% | Added |
| Intellectus Partners, LLC | 42,889 | $3.93M | 0.95% | +9,439+28.2% | Added |
| Bank of America Corp | 49,678 | $4.55M | 0.00% | +32,657+191.9% | Added |
| Citigroup Inc | 55,810 | $5.12M | 0.01% | −1,219−2.1% | Reduced |
| Susquehanna International Group, LLP | 59,031 | $5.41M | 0.01% | +10,893+22.6% | Added |
| Marshall Wace, LLP | 60,701 | $5.56M | 0.03% | +22,050+57.0% | Added |
| Bank of New York Mellon Corp | 61,326 | $5.62M | 0.00% | +5,978+10.8% | Added |
| Federated Hermes, Inc. | 62,115 | $5.69M | 0.01% | +30,519+96.6% | Added |
| Voloridge Investment Management, LLC | 69,545 | $6.37M | 0.04% | +36,367+109.6% | Added |
| Caption Management, LLC | 69,800 | $6.40M | 0.42% | +69,800 | New |
| Two Sigma Investments, LP | 73,075 | $6.70M | 0.02% | +36,928+102.2% | Added |
| Manufacturers Life Insurance Company, The | 78,246 | $7.17M | 0.01% | −33,325−29.9% | Reduced |
| Nuveen Asset Management, LLC | 80,877 | $7.41M | 0.00% | −16,475−16.9% | Reduced |
| Hennion & Walsh Asset Management, Inc. | 89,419 | $8.20M | 0.43% | +7,693+9.4% | Added |
| Citadel Advisors LLC | 94,182 | $8.63M | 0.01% | +94,182 | New |
| Price T Rowe Associates Inc | 94,554 | $8.67M | 0.00% | +55,154+140.0% | Added |
| Marshall Wace North America L.P. | 107,846 | $9.88M | 0.04% | +52,137+93.6% | Added |
| Charles Schwab Investment Management Inc | 124,151 | $11.4M | 0.00% | +18,304+17.3% | Added |
| Burleson & Company, LLC | 135,114 | $12.4M | 1.87% | +3,984+3.0% | Added |
| Alphabet Inc. | 189,122 | $17.3M | 0.41% | 00.0% | Unchanged |
| Northern Trust Corp | 200,748 | $18.4M | 0.00% | −4,366−2.1% | Reduced |
| Pacific Heights Asset Management LLC | 275,000 | $25.2M | 2.39% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 329,847 | $30.2M | 0.00% | +28,135+9.3% | Added |
| State Street Corp | 841,020 | $77.1M | 0.00% | −121,795−12.6% | Reduced |
| Vanguard Group Inc | 1,012,923 | $92.8M | 0.00% | +96,587+10.5% | Added |
| BlackRock Inc. | 1,325,048 | $121.5M | 0.00% | +40,476+3.2% | Added |
| Capital Research Global Investors | 2,315,839 | $212.3M | 0.05% | 00.0% | Unchanged |
| Capital International Investors | 2,975,851 | $272.8M | 0.06% | +239,182+8.7% | Added |
| Capital World Investors | 3,486,995 | $319.6M | 0.05% | +159,593+4.8% | Added |
| EPIQ Capital Group, LLC | 3,953,595 | $362.4M | 37.45% | +188,090+5.0% | Added |
| SC US (TTGP), Ltd. | 0 | $0 | 0.00% | −560,594−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −7,800−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −5,397−100.0% | Sold out |
| Blueshift Asset Management, LLC | 0 | $0 | 0.00% | −4,387−100.0% | Sold out |
| Harvard Management Co Inc | 0 | $0 | 0.00% | −2,937−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −2,300−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Nachman Norwood & Parrott, Inc | – | – | – | – | Not filed |